Skip Navigation

Adalvo advances in diabetes space, offering injectable and oral treatment alternatives

28 April 2022

Adalvo is one of the few companies who can offer a comprehensive diabetes portfolio covering small molecule oral treatments and complex peptide injectables. We understand that diabetes is becoming one of the fast-growing diseases, and we are focusing our attention on this domain, in order to satisfy the growing patient need for these products.

We have become a one-stop-shop solution for partners looking for diabetes products, offering a basket of seven dossiers, at a combined global market size of$40bn(according to IQVIA).

Our diabetes products include:

  • Dapagliflozin Film Coated Tablets (Forxiga, Astrazeneca)
  • Dapagliflozin + Metformin Film Coated Tablets (Xigduo, Astrazeneca)
  • Linagliptin Film Coated Tablets (Tradjenta, Boehringer Ingelheim)
  • Empagliflozin Film Coated Tablets (Jardiance, Boehringer Ingelheim)
  • Empagliflozin + Metformin Film Coated Tablets (Synjardy, Boehringer Ingelheim)
  • Liraglutide Pre-Filled Syringe (Victoza, Novo Nordisk)
  • Semaglutide Pre-Filled Syringe (Ozempic, Novo Nordisk)

We will continue to grow our portfolio offerings in this domain, further highlighting our ability to offer differentiated, value-added products to our partners.

Partner up now!

At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward. – Central Europe, Russia & CIS – South Europe & Israel North Europe, APAC and MENA, – Central East Europe & Brazil – LATAM (Exc. Brazil) – UK/Ireland, North America & South Africa - Head of Global BD&L

Disclaimer: products which are subject to patent protection are currently not offered or made available in countries where patents are in force.